Concentration-effect Relationship of Enoxaparin for Thromboembolic

Status Withdrawn

Clinical Trial Summary

Patients with COVID-19 have special demographic characteristics including thromboembolic risk factors .

The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit patient are not described.

Finally, given the lack of knowledge on the pharmacokinetic/pharmacodynamic properties of enoxaparin in intensive care unit patients infected with SARS-CoV-2, we propose to conduct a prospective multicenter cohort study to collect the biological data necessary for its study.

Clinical Trial Description

D-dimers greater than 1 μg/mL are a prognostic factor for 28-day mortality (odds ratio=18, 2-128). The use of preventive doses of enoxaparin (4,000 to 6,000 anti-Xa per day) or unfractionated heparin (10,000 to 15,000 IU per day) has been associated with a reduction in mortality of approximately one-third in patients with D-dimer levels greater than 3 μg/mL or those with sepsis-induced coagulopathy (SIC (sepsis-induced coagulopathy) score > 4)

For the intensive care unit patient, the preventive enoxaparin dosages were increased to 4,000 anti-Xa IU twice daily and to 6,000 anti-Xa IU twice daily if the patient weighs more than 120 kg. Curative treatment is even proposed in cases of marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen > 8 g/L or D-Dimer > 3 μg/mL or 3000 ng/mL) even without symptomatic thrombosis.

Given the lack of data on the use of these high "prophylactic" doses of enoxaparin, it is proposed that anti-Xa activity be monitored after the 3rd injection, and then regularly in the event of renal failure (because LMWHs are renally eliminated), to look for overdosage exposing a higher risk of bleeding. It is also proposed to regularly monitor (at least every 48 hours) the hemostasis of patients in search of multivisceral failure, or of coagulopathy of consumption which will require a re-evaluation of the heparin therapy dosage, these events being associated with an increased risk of haemorrhage. ;

Study Design

Related Conditions & MeSH terms

Sars-CoV2

Clinical Trial Details

NCT number	NCT04520620
Study type	Interventional
Source	Centre Hospitalier Universitaire de Saint Etienne
Contact
Status	Withdrawn
Phase	Phase 4
Start date	May 2, 2020
Completion date	July 10, 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04446065` - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers	Phase 2/Phase 3
Completed	`NCT04419025` - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease	Phase 2
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Completed	`NCT04463004` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	Phase 2
Completed	`NCT04446429` - Anti-Androgen Treatment for COVID-19	N/A
Completed	`NCT04402957` - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	Phase 2
Recruiting	`NCT04441372` - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Recruiting	`NCT04581148` - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Completed	`NCT04530604` - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)	Phase 1
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Active, not recruiting	`NCT04635605` - Methylene Blue Treatment of COVID-19	Phase 2
Recruiting	`NCT04395599` - Risk of Air Contamination During Visceral Surgery in COVID19 Patients	N/A
Recruiting	`NCT04472585` - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04411433` - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	Phase 3
Completed	`NCT04359706` - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting	`NCT04395794` - SARS-CoV-2 Disguise Study
Completed	`NCT04386551` - Detection of COVID-19 in Saliva Collection
Recruiting	`NCT04403269` - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE	Phase 2
Withdrawn	`NCT04379492` - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19	Phase 2
Completed	`NCT04379336` - BCG Vaccination for Healthcare Workers in COVID-19 Pandemic	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention — COV-ENOX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms